Plant Protein Product Stopped Infringing in Transit, Court Told

A Chinese maker of a plant-based protein told a US appeals court Tuesday that while its product may have run afoul of a US patent when it was made, its composition changed during shipment and storage so that it couldn’t have been infringing when it actually arrived in the US.

Wuhan Healthgen Biotechnology Corp. is appealing a US International Trade Commission order barring imports of its clinical-grade rice-derived recombinant human serum albumin, or rHSA, products. The company told a three-judge panel at the US Court of Appeals for the Federal Circuit that its product may once have met a key ...